Literature DB >> 27364510

Neurotrophin Receptor-Interacting Melanoma Antigen-Encoding Gene Homolog is Associated with Malignant Phenotype of Gastric Cancer.

Mitsuro Kanda1, Dai Shimizu2, Tsutomu Fujii2, Haruyoshi Tanaka2, Yuri Tanaka2, Kazuhiro Ezaka2, Masahiro Shibata2, Hideki Takami2, Ryoji Hashimoto2, Satoshi Sueoka2, Naoki Iwata2, Daisuke Kobayashi2, Chie Tanaka2, Suguru Yamada2, Goro Nakayama2, Hiroyuki Sugimoto2, Masahiko Koike2, Michitaka Fujiwara2, Yasuhiro Kodera2.   

Abstract

BACKGROUND: Identification of novel molecules implicated in the malignancy of gastric cancer (GC) is key to the development of personalized treatments and the improvement of patient outcome. Neurotrophin receptor-interacting melanoma antigen-encoding protein (NRAGE) regulates apoptosis and metastasis via interactions with various genes. This study aimed to evaluate the function and clinical significance of NRAGE in GC.
METHODS: The expression of NRAGE and its putative interacting genes apoptosis antagonizing transcription factor (AATF), p75 neurotrophin receptor (p75NTR), and proliferating cell nuclear antigen (PCNA) were determined in GC cell lines using reverse transcription-polymerase chain reaction (RT-PCR). The effect of NRAGE knockdown by small interfering RNA (siRNA) on GC cell behavior also was evaluated. In addition, NRAGE expression was determined in 179 pairs of resected gastric tissues.
RESULTS: Expression of NRAGE mRNA positively correlated with that of AATF, and NRAGE knockdown significantly decreased the proliferation, migration, and invasion of GC cells. The mean level of NRAGE mRNA expression was significantly higher in GC tissues than in corresponding adjacent normal tissues. The expression patterns of NRAGE mRNA and protein were closely correlated. A stepwise elevation in NRAGE mRNA expression in GC tissues was observed with increasing Union for International Cancer Control (UICC) stage. High NRAGE expression in GCs was associated with shortened recurrence-free survival and identified as an independent prognostic factor (hazard ratio, 1.83; 95 % CI, 1.12-3.02, p = 0.017).
CONCLUSIONS: The results indicate that NRAGE represents a putative oncogene associated with a malignant phenotype of GC. In GC, NRAGE may serve as a predictive biomarker and a target of molecular therapy.

Entities:  

Year:  2016        PMID: 27364510     DOI: 10.1245/s10434-016-5375-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

Review 1.  Molecular mechanisms of peritoneal dissemination in gastric cancer.

Authors:  Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

2.  NRAGE Confers Radiation Resistance in 2D and 3D Cell Culture and Poor Outcome in Patients With Esophageal Squamous Cell Carcinoma.

Authors:  Huandi Zhou; Guohui Wang; Zhiqing Xiao; Yu Yang; Zhesen Tian; Chen Gao; Xuetao Han; Wei Sun; Liubing Hou; Junling Liu; Xiaoying Xue
Journal:  Front Oncol       Date:  2022-04-01       Impact factor: 5.738

3.  A seven-gene prognostic signature for rapid determination of head and neck squamous cell carcinoma survival.

Authors:  Sipeng Shen; Jianling Bai; Yongyue Wei; Guanrong Wang; Qingya Li; Ruyang Zhang; Weiwei Duan; Sheng Yang; Mulong Du; Yang Zhao; David C Christiani; Feng Chen
Journal:  Oncol Rep       Date:  2017-10-24       Impact factor: 3.906

4.  Tanshinone IIA suppresses gastric cancer cell proliferation and migration by downregulation of FOXM1.

Authors:  Jiao Yu; Xiaoxia Wang; Yuhua Li; Bin Tang
Journal:  Oncol Rep       Date:  2017-01-30       Impact factor: 3.906

5.  A novel dual-marker expression panel for easy and accurate risk stratification of patients with gastric cancer.

Authors:  Mitsuro Kanda; Kenta Murotani; Haruyoshi Tanaka; Takashi Miwa; Shinichi Umeda; Chie Tanaka; Daisuke Kobayashi; Masamichi Hayashi; Norifumi Hattori; Masaya Suenaga; Suguru Yamada; Goro Nakayama; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Cancer Med       Date:  2018-05-07       Impact factor: 4.452

6.  Silencing of integrin subunit α3 inhibits the proliferation, invasion, migration and autophagy of esophageal squamous cell carcinoma cells.

Authors:  Jin Du; Yang Zhao; Dinghui Hu; Hang Li; Lei Gao; Zuntao Liu; Kaihu Shi
Journal:  Oncol Lett       Date:  2022-06-20       Impact factor: 3.111

7.  Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.

Authors:  Yi Zhou; Zhigang Ji; Weigang Yan; Zhien Zhou; Hanzhong Li; Yu Xiao
Journal:  Oncol Rep       Date:  2017-06-29       Impact factor: 3.906

8.  Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma.

Authors:  Shinichi Umeda; Mitsuro Kanda; Hiroyuki Sugimoto; Haruyoshi Tanaka; Masamichi Hayashi; Suguru Yamada; Tsutomu Fujii; Hideki Takami; Yukiko Niwa; Naoki Iwata; Chie Tanaka; Daisuke Kobayashi; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  BMC Cancer       Date:  2017-09-01       Impact factor: 4.430

9.  Integrated multigene expression panel to prognosticate patients with gastric cancer.

Authors:  Mitsuro Kanda; Kenta Murotani; Haruyoshi Tanaka; Takashi Miwa; Shinichi Umeda; Chie Tanaka; Daisuke Kobayashi; Masamichi Hayashi; Norifumi Hattori; Masaya Suenaga; Suguru Yamada; Goro Nakayama; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Oncotarget       Date:  2018-04-10

Review 10.  The Pattern of Signatures in Gastric Cancer Prognosis.

Authors:  Julita Machlowska; Ryszard Maciejewski; Robert Sitarz
Journal:  Int J Mol Sci       Date:  2018-06-04       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.